Resumé
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Acta Physiologica |
| Vol/bind | 219 |
| Udgave nummer | 2 |
| Sider (fra-til) | 346-361 |
| Antal sider | 16 |
| ISSN | 1748-1708 |
| DOI | |
| Status | Udgivet - jan. 2017 |
Citer dette
}
MicroRNAs in Metabolism. / Vienberg, Sara; Geiger, Julian; Madsen, Søren; Dalgaard, Louise Torp.
I: Acta Physiologica, Bind 219, Nr. 2, 01.2017, s. 346-361.Publikation: Bidrag til tidsskrift › Review › Forskning › peer review
TY - JOUR
T1 - MicroRNAs in Metabolism
AU - Vienberg, Sara
AU - Geiger, Julian
AU - Madsen, Søren
AU - Dalgaard, Louise Torp
PY - 2017/1
Y1 - 2017/1
N2 - MicroRNAs (miRNAs) have within the past decade emerged as key regulators of metabolic homoeostasis. Major tissues in intermediary metabolism important during development of the metabolic syndrome, such as β-cells, liver, skeletal and heart muscle as well as adipose tissue, have all been shown to be affected by miRNAs. In the pancreatic β-cell, a number of miRNAs are important in maintaining the balance between differentiation and proliferation (miR-200 and miR-29 families) and insulin exocytosis in the differentiated state is controlled by miR-7, miR-375 and miR-335. MiR-33a and MiR-33b play crucial roles in cholesterol and lipid metabolism, whereas miR-103 and miR-107 regulates hepatic insulin sensitivity. In muscle tissue, a defined number of miRNAs (miR-1, miR-133, miR-206) control myofibre type switch and induce myogenic differentiation programmes. Similarly, in adipose tissue, a defined number of miRNAs control white to brown adipocyte conversion or differentiation (miR-365, miR-133, miR-455). The discovery of circulating miRNAs in exosomes emphasizes their importance as both endocrine signalling molecules and potentially disease markers. Their dysregulation in metabolic diseases, such as obesity, type 2 diabetes and atherosclerosis stresses their potential as therapeutic targets. This review emphasizes current ideas and controversies within miRNA research in metabolism
AB - MicroRNAs (miRNAs) have within the past decade emerged as key regulators of metabolic homoeostasis. Major tissues in intermediary metabolism important during development of the metabolic syndrome, such as β-cells, liver, skeletal and heart muscle as well as adipose tissue, have all been shown to be affected by miRNAs. In the pancreatic β-cell, a number of miRNAs are important in maintaining the balance between differentiation and proliferation (miR-200 and miR-29 families) and insulin exocytosis in the differentiated state is controlled by miR-7, miR-375 and miR-335. MiR-33a and MiR-33b play crucial roles in cholesterol and lipid metabolism, whereas miR-103 and miR-107 regulates hepatic insulin sensitivity. In muscle tissue, a defined number of miRNAs (miR-1, miR-133, miR-206) control myofibre type switch and induce myogenic differentiation programmes. Similarly, in adipose tissue, a defined number of miRNAs control white to brown adipocyte conversion or differentiation (miR-365, miR-133, miR-455). The discovery of circulating miRNAs in exosomes emphasizes their importance as both endocrine signalling molecules and potentially disease markers. Their dysregulation in metabolic diseases, such as obesity, type 2 diabetes and atherosclerosis stresses their potential as therapeutic targets. This review emphasizes current ideas and controversies within miRNA research in metabolism
KW - adipocytes
KW - metabolism
KW - MicroRNA
KW - non-alcoholic hepato-steatosis
KW - type 2 diabetes mellitus
KW - β-cells
U2 - 10.1111/apha.12681
DO - 10.1111/apha.12681
M3 - Review
VL - 219
SP - 346
EP - 361
JO - Acta Physiologica (Print)
JF - Acta Physiologica (Print)
SN - 1748-1708
IS - 2
ER -